Results 61 to 70 of about 212,526 (280)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia

open access: yesCancers, 2023
Simple Summary Non-covalent Bruton’s tyrosine kinase inhibitors (ncBTKi) are being investigated for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL).
S. Montoya, Meghan C. Thompson
semanticscholar   +1 more source

MOESM10 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

open access: yes, 2019
Additional file 10: Table S1. Overview of antibodies used for experiments.
Heukels, Peter   +13 more
openaire   +1 more source

MOESM9 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

open access: yes, 2019
Additional file 9:. Graphic summary of B-cell subset alterations and autoreactive IgA induction in IPF patients. Immature B cells leave the bone marrow as transitional B-cells for further differentiation. Decrease in circulating transitional B-cells together with their increase in IPF lungs suggest homing towards pulmonary tertiary lymphoid organs (TLO)
Heukels, Peter   +13 more
openaire   +1 more source

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib

open access: yesCase Reports in Infectious Diseases, 2016
Cryptococcus is a unique environmental fungus that can cause disease most often in immunocompromised individuals with defective cell-mediated immunity. Chronic lymphocytic leukemia (CLL) is not known to be a risk factor for cryptococcal disease although ...
Koh Okamoto   +2 more
doaj   +1 more source

MOESM1 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

open access: yes, 2019
Additional file 1: Figure S1. No changes of proportions of total B-cells between controls and IPF patients. Flow cytometric quantification of total B-cells (CD19+) in blood, lungs and lymph nodes (LN) as percentage of alive cells. For blood samples data also depicted as absolute number of B-cells per ml blood.
Heukels, Peter   +13 more
openaire   +1 more source

Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL). [PDF]

open access: hybridCancer Chemother Pharmacol
Ouerdani A   +7 more
europepmc   +3 more sources

Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer [PDF]

open access: yes, 2004
X-linked agammaglobulinemia (XLA) is a human immunodeficiency caused by mutations in Bruton tyrosine kinase (Btk) and characterized by an arrest in early B-cell development, near absence of serum immunoglobulin, and recurrent bacteria infections.
Astrakhan, A.   +9 more
core   +1 more source

MOESM6 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

open access: yes, 2019
Additional file 6: Figure S6. Autoreactive IgG and IgM does not correlate with disease progression. Fluorescence intensity for plasma autoreactive IgG (A) and IgM (B) does not correlate with decline in forced vital capacity (FVC) over 1-year period in IPF patients. Correlation coefficients were calculated using Spearmanâ s rank method.
Heukels, Peter   +13 more
openaire   +1 more source

Characterization of the effects of BTK inhibition and monocyte-produced IL-8 on the hematopoietic stem cell niche [PDF]

open access: yes, 2020
Hematopoietic stem and progenitor cells (HSPCs) are multipotent stem cells that give rise to all blood cell lineages. During early zebrafish development, HSPCs interact closely with endothelial cells in an endothelial niche known as the Caudal ...
Belardo, Alexander
core  

MOESM7 of Enhanced Brutonâ s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis

open access: yes, 2019
Additional file 7: Figure S7. Gating strategy for B-cell subsets in mice. Representative gating strategy used for mice experiments for the identification of GC B-cells (CD19+CD95+IgDlow), IgA GC B-cells (CD19+CD95+IgDlowIgA+), plasma cells (CD19lowCD138+) and IgA+ plasma cells (CD19lowCD138+IgA+).
Heukels, Peter   +13 more
openaire   +1 more source

Home - About - Disclaimer - Privacy